New hope for stubborn melanoma: combo therapy targets hard-to-treat tumors
NCT ID NCT03131908
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 25 times
Summary
This study tests whether adding an experimental drug (GSK2636771) to an approved immunotherapy (pembrolizumab) can help control metastatic melanoma in patients whose tumors have a specific genetic change (PTEN loss). About 27 adults with advanced melanoma that didn't respond to prior treatments will receive the combination. The goal is to find the safest dose and see if the combo shrinks tumors or slows disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.